GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
3.060
+0.050 (1.66%)
Nov 22, 2024, 4:00 PM EST - Market closed
GT Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 6.42 | 1.08 | 5.67 | 8.97 | 5.3 | 0.03 | Upgrade
|
| Short-Term Investments | - | 12.89 | 10.84 | 23.01 | - | - | Upgrade
|
| Cash & Short-Term Investments | 6.42 | 13.97 | 16.51 | 31.98 | 5.3 | 0.03 | Upgrade
|
| Cash Growth | -59.92% | -15.36% | -48.38% | 503.72% | 18817.86% | -53.33% | Upgrade
|
| Prepaid Expenses | 0.25 | 0.08 | 0.05 | 0.19 | 0.36 | 0.25 | Upgrade
|
| Total Current Assets | 6.76 | 14.06 | 16.56 | 32.17 | 5.66 | 0.27 | Upgrade
|
| Property, Plant & Equipment | - | 0.05 | 0.17 | - | - | 0.11 | Upgrade
|
| Other Long-Term Assets | - | - | 0.01 | - | - | 0.01 | Upgrade
|
| Total Assets | 6.76 | 14.11 | 16.74 | 32.17 | 5.66 | 0.4 | Upgrade
|
| Accounts Payable | 2.61 | 4.33 | 3.14 | 8.19 | 2.24 | 1.94 | Upgrade
|
| Accrued Expenses | 1.87 | 1.2 | 1.67 | 1.9 | 6.13 | 4.41 | Upgrade
|
| Short-Term Debt | - | - | - | 0.03 | 26.33 | 13.24 | Upgrade
|
| Current Portion of Leases | - | 0.06 | 0.11 | - | - | 0.12 | Upgrade
|
| Other Current Liabilities | 0.18 | 1.05 | 0.02 | 0.14 | 0.38 | - | Upgrade
|
| Total Current Liabilities | 4.66 | 6.63 | 4.94 | 10.26 | 35.09 | 19.71 | Upgrade
|
| Long-Term Leases | - | - | 0.06 | - | - | - | Upgrade
|
| Total Liabilities | 4.66 | 6.63 | 5 | 10.26 | 35.09 | 19.71 | Upgrade
|
| Common Stock | 0 | 0 | 0.03 | 0.03 | 0.01 | 0.04 | Upgrade
|
| Additional Paid-In Capital | 693.55 | 689.54 | 686.17 | 674.35 | 566.36 | 548.15 | Upgrade
|
| Retained Earnings | -691.45 | -682.07 | -674.47 | -653.58 | -595.8 | -567.33 | Upgrade
|
| Comprehensive Income & Other | - | - | - | 1.11 | - | - | Upgrade
|
| Total Common Equity | 2.1 | 7.48 | 11.73 | 21.91 | -29.44 | -19.14 | Upgrade
|
| Minority Interest | - | - | - | - | - | -0.17 | Upgrade
|
| Shareholders' Equity | 2.1 | 7.48 | 11.73 | 21.91 | -29.43 | -19.31 | Upgrade
|
| Total Liabilities & Equity | 6.76 | 14.11 | 16.74 | 32.17 | 5.66 | 0.4 | Upgrade
|
| Total Debt | - | 0.06 | 0.17 | 0.03 | 26.33 | 13.36 | Upgrade
|
| Net Cash (Debt) | 6.42 | 13.91 | 16.33 | 31.95 | -21.04 | -13.33 | Upgrade
|
| Net Cash Growth | -59.69% | -14.82% | -48.87% | - | - | - | Upgrade
|
| Net Cash Per Share | 3.82 | 10.32 | 15.38 | 34.04 | -143.92 | -118.18 | Upgrade
|
| Filing Date Shares Outstanding | 2.23 | 1.38 | 1.23 | 1.07 | 0.95 | 0.14 | Upgrade
|
| Total Common Shares Outstanding | 2.23 | 1.38 | 1.09 | 1.07 | 0.17 | 0.14 | Upgrade
|
| Working Capital | 2.1 | 7.42 | 11.62 | 21.91 | -29.43 | -19.43 | Upgrade
|
| Book Value Per Share | 0.94 | 5.41 | 10.76 | 20.50 | -169.23 | -139.91 | Upgrade
|
| Tangible Book Value | 2.1 | 7.48 | 11.73 | 21.91 | -29.44 | -19.14 | Upgrade
|
| Tangible Book Value Per Share | 0.94 | 5.41 | 10.76 | 20.50 | -169.23 | -139.91 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.